Table 3.
Adjusted odds ratio (AOR) and 95% confidence interval (CI) of clinical status and CD44 rs187115 genotypic frequencies in 203 HCC patients.
| Variable | Genotypic frequencies | |||
|---|---|---|---|---|
| AA (N = 123) | AG+GG (N = 80) | OR (95% CI) | AOR (95% CI) | |
| n (%) | n (%) | |||
| Clinical stage | ||||
| Stage I/II | 81 (65.9%) | 46 (57.5%) | 1.00 | 1.00 |
| Stage III/IV | 42 (34.1%) | 34 (42.5%) | 1.425 (0.799–2.544) | 1.754 (0.818–3.760) |
| Tumor size | ||||
| ≦T2 | 81 (65.9%) | 48 (60.0%) | 1.00 | 1.00 |
| >T2 | 42 (34.1%) | 32 (40.0%) | 1.286 (0.718–2.301) | 1.375 (0.639–2.960) |
| Lymph node metastasis | ||||
| No | 120 (97.6%) | 74 (92.5%) | 1.00 | 1.00 |
| Yes | 3 (2.4%) | 6 (7.5%) | 3.243 (0.787–13.362) | 5.024 (0.892–28.309) |
| Distant metastasis | ||||
| No | 118 (95.9%) | 74 (92.5%) | 1.00 | 1.00 |
| Yes | 5 (4.1%) | 6 (7.5%) | 1.914 (0.564–6.494) | 3.360 (0.600–18.226) |
| The Child-Pugh grade | ||||
| A | 89 (72.4%) | 58 (72.5%) | 1.00 | 1.00 |
| B or C | 34 (27.6%) | 22 (27.5%) | 0.993 (0.529–1.864) | 1.208 (0.534–2.731) |
| HBsAg | ||||
| Negative | 73 (59.3%) | 46 (57.5%) | 1.00 | 1.00 |
| Positive | 50 (40.7%) | 34 (42.5%) | 1.079 (0.610–1.910) | 1.153 (0.538–2.471) |
| Anti-HCV | ||||
| Negative | 67 (54.5%) | 40 (50.0%) | 1.00 | 1.00 |
| Positive | 56 (45.5%) | 40 (50.0%) | 1.196 (0.681–2.103) | 1.075 (0.526–2.198) |
| Liver cirrhosis | ||||
| Negative | 30 (24.4%) | 26 (32.5%) | 1.00 | 1.00 |
| Positive | 93 (75.6%) | 54 (67.5%) | 0.670 (0.359–1.249) | 0.500 (0.220–1.133) |
The ORs analyzed by their 95% CIs were estimated by logistic regression models.
The AORs with their 95% CI were estimated by multiple logistic regression models, after controlling for age, gender, and tobacco and alcohol consumption.
>T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s).